Coronavirus / COVID

Covaxx has developed its investigational vaccine and is currently in a phase 1/2 trial.

Pfizer anticipates to have completed FDA-mandated safety data a month from now. An EUA application should shortly follow.

The investigators looked at data from all adult coronavirus-related deaths between March and May 2020.

Commentary highlights importance, recommends steps to continuing surgical practice during pandemic.

Data from a Phase 1/2 randomized controlled trial of vaccine candidate, BBIBP-CorV, is shown to be safe.

A new study found most early cases of SARS-CoV-2 infection in Southern California were seeded from Europe rather than Asia, thus shedding light on how the pathogen spread in the United States.

A letter signed by 80 researchers says the concept put forth by the Great Barrington Declaration is “a dangerous fallacy.”

Looking at certain characteristics in a blood test can help forecast patients’ course and inform clinicians’ determination on the course of treatment.

Patients who are at highest risk of progression to severe COVID-19 are older patients, those with comorbidities, and those living in nursing homes.

Underlying chronic obstructive pulmonary disease in patients infected with COVID-19 present a variety of challenges for health care professionals, including increased risk for poor clinical outcomes and increased risk of spreading the disease.

A recently proposed effort toward herd immunity through younger person COVID-19 infection was met with contention from public health leaders and experts.

This action comes less than 24 hours after the J&J vaccine was paused.

A 25-year-old male in Nevada was hospitalized due to a different SARS-CoV-2 strain 2 months after recovering from a first case.

The BioGX’s Xfree COVID-19 Direct RT-PCR test has the potential to increase testing capacity by millions per week.

New UK population study shows majority of those who test positive did not have typical symptoms associated with the virus.

Abbott’s IgM test offer high specificity and sensitivity 15 days after onset of symptoms.

Fundamental aspects of immunity to SARS-CoV-2 remain elusive. Here is an examination of some potential clues to protection.

A collection of expert perspectives on what the virus itself may mean for future crises.

Influenza vaccination during COVID-19 could keep health resources from being overwhelmed and mitigate cardiovascular risks.

Results from a study suggest that the effects of the virus on the brain may be more profound than respiratory symptoms.

New ACTT-2 data shows a marked benefit from the combination regimen versus lone remdesivir.

RECOVERY trial reported hospitalized COVID-19 patients did not see a benefit compared to those patients who received usual care.

ACTT-1 findings for the Gilead antiviral show it improved chance of clinical improvement by 50% in very ill COVID-19 patients.